Chemical Property of Synercid
Edit
Chemical Property:
- Boiling Point:°Cat760mmHg
- Flash Point:°C
- Density:g/cm3
- Hydrogen Bond Donor Count:6
- Hydrogen Bond Acceptor Count:25
- Rotatable Bond Count:17
- Exact Mass:1711.80301090
- Heavy Atom Count:121
- Complexity:3350
- Purity/Quality:
-
99% *data from raw suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
Useful:
- Canonical SMILES:CCC1C(=O)N2CCCC2C(=O)N(C(C(=O)N3CC(C(=O)CC3C(=O)NC(C(=O)OC(C(C(=O)N1)NC(=O)C4=C(C=CC=N4)O)C)C5=CC=CC=C5)CSC6CN7CCC6CC7)CC8=CC=C(C=C8)N(C)C)C.CCN(CC)CCS(=O)(=O)C1CCN2C1C(=O)OC(C(C=CC(=O)NCC=CC(=CC(CC(=O)CC3=NC(=CO3)C2=O)O)C)C)C(C)C
- Isomeric SMILES:CC[C@@H]1C(=O)N2CCC[C@H]2C(=O)N([C@H](C(=O)N3C[C@H](C(=O)CC3C(=O)N[C@H](C(=O)O[C@@H]([C@@H](C(=O)N1)NC(=O)C4=C(C=CC=N4)O)C)C5=CC=CC=C5)CS[C@@H]6CN7CCC6CC7)CC8=CC=C(C=C8)N(C)C)C.CCN(CC)CCS(=O)(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@@H]([C@@H](/C=C/C(=O)NC/C=C/C(=C/[C@H](CC(=O)CC3=NC(=CO3)C2=O)O)/C)C)C(C)C
- Recent ClinicalTrials:Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients
-
Description
Dalfopristin and Quinupristin are two well-defined semi-synthetic
antibacterials belonging to the class of streptogramins. Together, they form
Synercid, an injectable formulation in a ratio 70 : 30 that was launched in the UK followed by the US. The two distinct antibiotic agents,
pristinamycins, are bacteriostatic in their own right but, when they are in
association, act synergistically at the ribosomal level to inhibit protein synthesis.
Synercid is the first antibiotic in its class to reach the market. It appears to be a
sound treatment alternative for patients with severe or life-threatening infections,
such as the most problematic forms of gram-positive nosocomial sepsis
including vancomycin-resistant Enterococcus faecium (VREF) or methicillinresistant
Staphylococcus aureus (MRSA).
-
Uses
Quinupristin-dalfopristin mesylate complex is a 70:30 complex that functions as an antibiotic. Quinupristin-dalfopristin mesylate complex is a 70:30 (w/w) complex of two semi-synthetic analogues marketed as SynercidTM. Dalfopristin is a semisynthetic analogue of virginiamycin M, while quinupristin is a semi-synthetic analogue of virginiamycin B. To optimise stability, the compounds are presented as the mesylate salts with 10% sodium mesylate excess to provide a buffered aqueous solution. The complex is more hydrophobic than the naturally-occurring virginiamycin complex, with a readily ionisable group for generating a salt for improved solubility. There is little published data on the synthesis and biological activity of individual components of the complex, however the combination is a highly effective antibiotic, including activity against resistant strains.
